UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells

Cell metabolism, 2015-12, Vol.22 (6), p.1009-1019

2015

Volltextzugriff (PDF)

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

Proceedings of the National Academy of Sciences - PNAS, 2015-05, Vol.112 (21), p.6539-6544

2015

Volltextzugriff (PDF)

MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity

eLife, 2020-01, Vol.9

2020

Volltextzugriff (PDF)

MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase

Cancer research (Chicago, Ill.), 2011-03, Vol.71 (6), p.2286-2297

2011

Volltextzugriff (PDF)

SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas

PloS one, 2012-09, Vol.7 (9), p.e45119

2012

Volltextzugriff (PDF)

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

mAbs, 2021-01, Vol.13 (1), p.1981202-1981202

2021

Volltextzugriff (PDF)

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

Investigational new drugs, 2020-04, Vol.38 (2), p.457-467

2020

Volltextzugriff (PDF)

MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC

Molecular therapy. Nucleic acids, 2020-09, Vol.21, p.850-859

2020

Volltextzugriff (PDF)

Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (23), p.10938-10945

2005

Volltextzugriff (PDF)

Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas

PloS one, 2008-05, Vol.3 (5), p.e2125

2008

Volltextzugriff (PDF)

Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis

PloS one, 2008-06, Vol.3 (6), p.e2493-e2493

2008

Volltextzugriff (PDF)

MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes

Oncogene, 2022-11, Vol.41 (45), p.4960-4970

2022

Volltextzugriff (PDF)

Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice

Molecular therapy, 2010-01, Vol.18 (1), p.161-170

2010

Volltextzugriff (PDF)

Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs

Advances in experimental medicine and biology, 2013, Vol.734, p.91

2013

Volltextzugriff (PDF)

Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma

The Journal of clinical investigation, 2005-02, Vol.115 (2), p.339-347

2005

Volltextzugriff (PDF)

Characterization of MYC-Induced Tumorigenesis by in Situ Lipid Profiling

Analytical chemistry (Washington), 2013-05, Vol.85 (9), p.4259-4262

2013

Volltextzugriff (PDF)

Noncanonical roles of the immune system in eliciting oncogene addiction

Current opinion in immunology, 2013-04, Vol.25 (2), p.246-258

2013

Volltextzugriff (PDF)

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

Cancer research communications, 2023-09, Vol.3 (9), p.1731-1742

2023

Volltextzugriff (PDF)

Abstract 1599: Antibody-based inhibition of CSF-1R as a component of combination immunotherapy in preclinical models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1599-1599

2017

Volltextzugriff (PDF)

Abstract 2594: Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2594-2594

2022

Volltextzugriff (PDF)

Abstract 613: Development of FPA154, a novel tetravalent anti-GITR antibody, for the treatment of solid tumors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.613-613

2017

Volltextzugriff (PDF)

Abstract 2845: Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2845-2845

2014

Volltextzugriff (PDF)

Abstract 1419: Oncogenic Myc disrupts NAMPT circadian oscillation in mouse hepatocellular carcinoma cell line

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1419-1419

2014

Volltextzugriff (PDF)

Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5449-5449

2014

Volltextzugriff (PDF)

Abstract 3590: ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3590-3590

2022

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Humans
(14)
Life Sciences & Biomedicine
(14)
Animals
(13)
Mice
(12)
Oncology
(11)
Mice, Transgenic
(8)
Tumors
(8)
Cell Line, Tumor
(7)
Gene Expression Regulation, Neoplastic
(6)
Proto-Oncogene Proteins C-Myc - Metabolism
(6)
Tumorigenesis
(6)
Cancer
(5)
Genes, Myc
(5)
Hepatocellular Carcinoma
(5)
Liver Cancer
(5)
Medicine
(5)
Myc Protein
(5)
Proto-Oncogene Proteins C-Myc - Genetics
(5)
Rodents
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity

MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase

SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC

Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease

Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas

Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis

MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes

Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice

Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs

Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma

Characterization of MYC-Induced Tumorigenesis by in Situ Lipid Profiling

Noncanonical roles of the immune system in eliciting oncogene addiction

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

Abstract 1599: Antibody-based inhibition of CSF-1R as a component of combination immunotherapy in preclinical models

Abstract 2594: Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor

Abstract 613: Development of FPA154, a novel tetravalent anti-GITR antibody, for the treatment of solid tumors

Abstract 2845: Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody

Abstract 1419: Oncogenic Myc disrupts NAMPT circadian oscillation in mouse hepatocellular carcinoma cell line

Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC

Abstract 3590: ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells

Suchergebnisse filtern